EGFR Phosphorylation Array
EGFR (P-Tyr845), EGFR (P-Tyr1148), ErbB2 (P-Tyr1112), ErbB3 (P-Tyr1289), EGFR (P-Tyr992), EGFR (P-Tyr1173), ErbB2 (P-Tyr 1221/1222), ErbB4 (P-Tyr1284), EGFR (P-Tyr1045), EGFR (P-Ser1046/1047), ErbB2 (P-Tyr1248), EGFR (P-Tyr1068), EGFR (P-Ser1070), ErbB2 (P-Thr686), EGFR (P-Tyr1086), ErbB2 (P-Tyr877), ErbB2 (P-Ser1113)
Serum, Plasma, Cell Culture Supernatant, Cell Lysates, Tissue Lysates
Multiplex Protein Detection
Incubate with Sample
Incubate with Biotinylated Detection Antibody Cocktail
Incubate with HRP-Conjugated Streptavidin
Incubate with Detection Buffers
Image with chemiluminescent imaging system
Perform densitometry and analysis
Antibody Array Membrane
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Once thawed, please keep reagents under suitable conditions respectively. Do not use past expiration date.
The epidermal growth factor receptor is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer. Deficient signaling of the EGFR and other receptor tyrosine kinases in humans is associated with diseases such as Alzheimer's, while over-expression is associated with the development of a wide variety of tumors. Interruption of EGFR signalling, either by blocking EGFR binding sites on the extracellular domain of the receptor or by inhibiting intracellular tyrosine kinase activity, can prevent the growth of EGFR-expressing tumours and improve the patient's condition.